The aim of this study is to compare the effectiveness of vitamin D and E vaginal suppository on vaginal atrophy in women with breast cancer who taking tamoxifen. Material and Method: this randomized, double blind controlled trial will carry out at in Motahari breast clinic, Shiraz. A total of 150 women with breast cancer with symptoms of vaginal atrophy are randomly assigned to three groups to receive vaginal suppositories. 50 patients will take placebo vaginal suppositories containing 2 gr base material, (Suppocire AS2), 50 patients will take vitamin D vaginal suppositories (1000 IU Vitamin D equivalent to 0/025 mg of vitamin D in addition to the base material), and 50 patients will take vitamin E vaginal suppositories (1 mg vitamin E in addition to the base material). Symptoms of vaginal atrophy are confirmed by assessing vaginal PH (by PH indicator strip, construction by Sigma-Aldrich Germany with accuracy of 0.5), measuring vaginal maturation index (VMI), and subjective symptoms of vaginal atrophy according to self-assessment urogenital atrophy questionnaire (UAQ). If vaginal atrophy is approved (PH Score of 5 or greater than 5, VMI score 52 or less and at least one of the items of the UAQ), 14 vaginal suppositories will be given to any person. After two weeks, the other 14 vaginal suppositories will be given and subjective symptoms of vaginal atrophy will be assessed by UAQ and the vaginal PH is measured. After two weeks, besides the delivery of the remaining 28 suppositories, subjective symptoms of vaginal atrophy is evaluated and vaginal PH is measured. Four weeks later, in addition to evaluating subjective symptoms of vaginal atrophy, vaginal PH level and the vaginal maturation index is also checked.